219 related articles for article (PubMed ID: 32020675)
1. DNA aptamers against the DUX4 protein reveal novel therapeutic implications for FSHD.
Klingler C; Ashley J; Shi K; Stiefvater A; Kyba M; Sinnreich M; Aihara H; Kinter J
FASEB J; 2020 Mar; 34(3):4573-4590. PubMed ID: 32020675
[TBL] [Abstract][Full Text] [Related]
2. Expression patterns of FSHD-causing DUX4 and myogenic transcription factors PAX3 and PAX7 are spatially distinct in differentiating human stem cell cultures.
Haynes P; Kernan K; Zhou SL; Miller DG
Skelet Muscle; 2017 Jun; 7(1):13. PubMed ID: 28637492
[TBL] [Abstract][Full Text] [Related]
3. PAX7 target gene repression is a superior FSHD biomarker than DUX4 target gene activation, associating with pathological severity and identifying FSHD at the single-cell level.
Banerji CRS; Zammit PS
Hum Mol Genet; 2019 Jul; 28(13):2224-2236. PubMed ID: 31067297
[TBL] [Abstract][Full Text] [Related]
4. A complex interplay of genetic and epigenetic events leads to abnormal expression of the DUX4 gene in facioscapulohumeral muscular dystrophy.
Gatica LV; Rosa AL
Neuromuscul Disord; 2016 Dec; 26(12):844-852. PubMed ID: 27816329
[TBL] [Abstract][Full Text] [Related]
5. An isogenetic myoblast expression screen identifies DUX4-mediated FSHD-associated molecular pathologies.
Bosnakovski D; Xu Z; Gang EJ; Galindo CL; Liu M; Simsek T; Garner HR; Agha-Mohammadi S; Tassin A; Coppée F; Belayew A; Perlingeiro RR; Kyba M
EMBO J; 2008 Oct; 27(20):2766-79. PubMed ID: 18833193
[TBL] [Abstract][Full Text] [Related]
6. p38
Rojas LA; Valentine E; Accorsi A; Maglio J; Shen N; Robertson A; Kazmirski S; Rahl P; Tawil R; Cadavid D; Thompson LA; Ronco L; Chang AN; Cacace AM; Wallace O
J Pharmacol Exp Ther; 2020 Sep; 374(3):489-498. PubMed ID: 32576599
[TBL] [Abstract][Full Text] [Related]
7. DUX4 Role in Normal Physiology and in FSHD Muscular Dystrophy.
Mocciaro E; Runfola V; Ghezzi P; Pannese M; Gabellini D
Cells; 2021 Nov; 10(12):. PubMed ID: 34943834
[TBL] [Abstract][Full Text] [Related]
8. PAX7 target genes are globally repressed in facioscapulohumeral muscular dystrophy skeletal muscle.
Banerji CRS; Panamarova M; Hebaishi H; White RB; Relaix F; Severini S; Zammit PS
Nat Commun; 2017 Dec; 8(1):2152. PubMed ID: 29255294
[TBL] [Abstract][Full Text] [Related]
9. Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular Dystrophy.
Oliva J; Galasinski S; Richey A; Campbell AE; Meyers MJ; Modi N; Zhong JW; Tawil R; Tapscott SJ; Sverdrup FM
J Pharmacol Exp Ther; 2019 Aug; 370(2):219-230. PubMed ID: 31189728
[TBL] [Abstract][Full Text] [Related]
10. G-quadruplex ligands mediate downregulation of DUX4 expression.
Ciszewski L; Lu-Nguyen N; Slater A; Brennan A; Williams HEL; Dickson G; Searle MS; Popplewell L
Nucleic Acids Res; 2020 May; 48(8):4179-4194. PubMed ID: 32182342
[TBL] [Abstract][Full Text] [Related]
11. DUX4 Signalling in the Pathogenesis of Facioscapulohumeral Muscular Dystrophy.
Lim KRQ; Nguyen Q; Yokota T
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31979100
[TBL] [Abstract][Full Text] [Related]
12. DNA-binding sequence specificity of DUX4.
Zhang Y; Lee JK; Toso EA; Lee JS; Choi SH; Slattery M; Aihara H; Kyba M
Skelet Muscle; 2016; 6():8. PubMed ID: 26823969
[TBL] [Abstract][Full Text] [Related]
13. BET bromodomain inhibitors and agonists of the beta-2 adrenergic receptor identified in screens for compounds that inhibit DUX4 expression in FSHD muscle cells.
Campbell AE; Oliva J; Yates MP; Zhong JW; Shadle SC; Snider L; Singh N; Tai S; Hiramuki Y; Tawil R; van der Maarel SM; Tapscott SJ; Sverdrup FM
Skelet Muscle; 2017 Sep; 7(1):16. PubMed ID: 28870238
[TBL] [Abstract][Full Text] [Related]
14. A feedback loop between nonsense-mediated decay and the retrogene DUX4 in facioscapulohumeral muscular dystrophy.
Feng Q; Snider L; Jagannathan S; Tawil R; van der Maarel SM; Tapscott SJ; Bradley RK
Elife; 2015 Jan; 4():. PubMed ID: 25564732
[TBL] [Abstract][Full Text] [Related]
15. The DUX4 homeodomains mediate inhibition of myogenesis and are functionally exchangeable with the Pax7 homeodomain.
Bosnakovski D; Toso EA; Hartweck LM; Magli A; Lee HA; Thompson ER; Dandapat A; Perlingeiro RCR; Kyba M
J Cell Sci; 2017 Nov; 130(21):3685-3697. PubMed ID: 28935672
[TBL] [Abstract][Full Text] [Related]
16. Facioscapulohumeral dystrophy transcriptome signatures correlate with different stages of disease and are marked by different MRI biomarkers.
van den Heuvel A; Lassche S; Mul K; Greco A; San León Granado D; Heerschap A; Küsters B; Tapscott SJ; Voermans NC; van Engelen BGM; van der Maarel SM
Sci Rep; 2022 Jan; 12(1):1426. PubMed ID: 35082321
[TBL] [Abstract][Full Text] [Related]
17. Endogenous DUX4 expression in FSHD myotubes is sufficient to cause cell death and disrupts RNA splicing and cell migration pathways.
Rickard AM; Petek LM; Miller DG
Hum Mol Genet; 2015 Oct; 24(20):5901-14. PubMed ID: 26246499
[TBL] [Abstract][Full Text] [Related]
18. DUX4-induced constitutive DNA damage and oxidative stress contribute to aberrant differentiation of myoblasts from FSHD patients.
Dmitriev P; Bou Saada Y; Dib C; Ansseau E; Barat A; Hamade A; Dessen P; Robert T; Lazar V; Louzada RAN; Dupuy C; Zakharova V; Carnac G; Lipinski M; Vassetzky YS
Free Radic Biol Med; 2016 Oct; 99():244-258. PubMed ID: 27519269
[TBL] [Abstract][Full Text] [Related]
19. Crystal Structure of the Double Homeodomain of DUX4 in Complex with DNA.
Lee JK; Bosnakovski D; Toso EA; Dinh T; Banerjee S; Bohl TE; Shi K; Orellana K; Kyba M; Aihara H
Cell Rep; 2018 Dec; 25(11):2955-2962.e3. PubMed ID: 30540931
[TBL] [Abstract][Full Text] [Related]
20. A distal auxiliary element facilitates cleavage and polyadenylation of Dux4 mRNA in the pathogenic haplotype of FSHD.
Peart N; Wagner EJ
Hum Genet; 2017 Sep; 136(9):1291-1301. PubMed ID: 28540412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
